Daiichi Sankyo Company, Limited (4568.T) JPX

2,522.50

-60(-2.32%)

Updated at June 03 03:24PM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Hiroyuki Okuzawa	President, Chief Executive Officer & Representative Director	215M	1962
Joji Nakayama	Senior Adviser	154M	1950
Sunao Manabe	Executive Chairperson	302M	1954
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	0	1963
Kentaro Murakawa	President of Daiichi Sankyo Espha Co., Ltd.	0	1959
Takashi Matsumoto	Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director	0	1964
Tetsuya Ohira	Corporate Officer, Head of Business Transformation & CTO	0	N/A
Thierry Gruson	Head of Global Oncology Marketing	0	N/A
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	0	N/A
Koji Ogawa	Senior Exe. Off., Head of Corporate Planning & Mgt. and Chief Financial Officer	0	N/A
Stuart Mackey	Global Head of Business Development	0	N/A
Hiroto Kashiwase	Executive Officer & Head of Technology Division	0	N/A
Kentaro Asakura	Corporate Officer and Head of Corporate Communications Dept, Global Corporate Planning & Mngmt	0	N/A
Tomohiro Kodama	Senior Executive Officer, Head of Global Corporate Planning & Management and CFO	0	N/A
Naoto Tsukaguchi	Senior Executive Officer, Head of Global Legal & IP, GC	0	N/A
Kenji Katsumi	President of Daiichi Sankyo Business Associe Co., Ltd.	0	N/A

Name

Title

Pay

Year Born

Hiroyuki Okuzawa

President, Chief Executive Officer & Representative Director

215M

1962

Joji Nakayama

Senior Adviser

154M

1950

Sunao Manabe

Executive Chairperson

302M

1954

Joseph Kenneth Keller

Head of Oncology Business Unit & Global Oncology Business and Director

1963

Kentaro Murakawa

President of Daiichi Sankyo Espha Co., Ltd.

1959

Takashi Matsumoto

Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director

1964

Tetsuya Ohira

Corporate Officer, Head of Business Transformation & CTO

N/A

Thierry Gruson

Head of Global Oncology Marketing

N/A

Matt Allegrucci

Head of Global Compliance & Risk Management and Chief Compliance Officer

N/A

Koji Ogawa

Senior Exe. Off., Head of Corporate Planning & Mgt. and Chief Financial Officer

N/A

Stuart Mackey

Global Head of Business Development

N/A

Hiroto Kashiwase

Executive Officer & Head of Technology Division

N/A

Kentaro Asakura

Corporate Officer and Head of Corporate Communications Dept, Global Corporate Planning & Mngmt

N/A

Tomohiro Kodama

Senior Executive Officer, Head of Global Corporate Planning & Management and CFO

N/A

Naoto Tsukaguchi

Senior Executive Officer, Head of Global Legal & IP, GC

N/A

Kenji Katsumi

President of Daiichi Sankyo Business Associe Co., Ltd.

N/A

Description

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.